Larimar Therapeutics Inc.

NASDAQ: LRMR · Real-Time Price · USD
4.23
-0.03 (-0.70%)
At close: Aug 15, 2025, 12:44 PM

Larimar Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 311K 272K 326K
Gross Profit
n/a -311K -272K -326K
Operating Income
-90.89M -41.76M -36.53M -50.47M
Interest Income
n/a n/a n/a n/a
Pretax Income
-80.6M -36.95M -35.35M -50.64M
Net Income
-80.6M -36.95M -34.18M -50.31M
Selling & General & Admin
17.61M 14.09M 12.28M 12.07M
Research & Development
72.96M 27.36M 24.25M 38.4M
Other Expenses
n/a n/a n/a -171K
Operating Expenses
90.89M 41.76M 36.53M 50.47M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 41.76M 36.53M 50.47M
Income Tax Expense
n/a n/a -1.17M -326K
Shares Outstanding (Basic)
61.26M 43.9M 25.76M 17.16M
Shares Outstanding (Diluted)
61.26M 43.9M 25.76M 17.16M
EPS (Basic)
-1.32 -0.84 -1.33 -2.93
EPS (Diluted)
-1.32 -0.84 -1.33 -2.93
EBITDA
-80.29M -41.45M -35.08M -50.14M
EBIT
n/a -41.76M -36.53M -50.64M
Depreciation & Amortization
n/a 311K 272K 326K